poisar

Stocks · News reference

HC Wainwright & Co. Reiterates Buy on Prelude Therapeutics, Maintains $8 Price Target

Benzinga Newsdesk

HC Wainwright & Co. analyst Robert Burns reiterates Prelude Therapeutics (NASDAQ:PRLD) with a Buy and maintains $8 price target.

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

PRLD
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  3. Benzinga Newsdesk

    Prelude Therapeutics Receives FDA Clearance To Proceed With A Phase 1 Study Under Its Investigational New Drug Application For PRT13722 For The Treatment Of Patients With HR+/HER2- Breast Cancer; Expects To Begin Enrolling Patients In Q4 2026

    "Recent clinical data validated KAT6 as a targetable mechanism in the treatment of HR+/HER2- breast cancer, including those with actionable mutations," stated Charles Morris, MBChB, MRCP, Chief Medical Officer

    PRLD